

## **By 2023, 100% of ESTEVE's commercial fleet will be plug-in hybrid and electric cars**

- **This initiative is part of the company's fight against climate change, along with several other projects it is carrying out**
- **These include the future installation of solar panels for self-consumption at its Spanish plants in Celrà and Banyeres and its collaboration in a new wind farm in China**
- **The ultimate goal is to advance in a model of economic, social and environmentally sustainable development that will help to achieve the SDGs**

**Barcelona, June 3, 2021** - ESTEVE, a company committed to protecting the environment, believes that the fight against climate change and health are directly related. In order to reduce its carbon footprint, it is working on various global and local projects. These include the renewal of its entire fleet of vehicles over the next three years in order to have 100% plug-in hybrid and electric vehicles by 2023, the installation of photovoltaic panels at its plants in Spain in the second half of 2021 - meaning that 10% of its total energy consumption will come from solar panels - and its collaboration in a new wind farm in China, which has enabled it to offset 665 tonnes of CO<sub>2</sub>.

The fight against climate change is strategic for ESTEVE. The company has a positioning in this area that reflects its ambition and its lines of action, with global initiatives and a clear awareness of the need to act on a daily basis.

*"Our vision of a low-emission future involves continuing to advance towards a model of sustainable economic, social and environmental development, contributing to achieving the goals of the 2030 Agenda," explains Isabel Robles, Global EHS Director at ESTEVE. "We prioritize the consumption of energy from renewable sources, and implement initiatives aimed at energy efficiency, minimizing the consumption of resources such as water or mobility and sustainable behaviors".* In May 2020, ESTEVE updated its Global Prevention and Environment Policy to include its commitment to and position on climate change.

### **Emission reductions and offsets**

In emissions reduction, ESTEVE has renewed its commitment to the Voluntary Agreements Program and the Ministry for Ecological Transition's Carbon Footprint Registry, committing to monitoring emissions reduction through the aforementioned initiatives.

ESTEVE will renew its entire commercial fleet with new Volkswagen plug-in hybrid vehicles that produce a third of the emissions of a diesel vehicle. In the last year, in 2020,



the company added a total of 57 plug-in hybrid vehicles and from now until 2023 it will continue introduce new models.

Last year, 75% of the electricity grid consumption at ESTEVE's production centers in Spain came from renewable sources and the company continues to work to reach 100% through specific contracts for the supply of this type of energy in 2021. In this regard, or particular note is the project to install photovoltaic panels to generate approximately 10% of the energy demand of its factories in Celrà (Girona) and Banyeres (Tarragona) by 2022 through self-consumption.

As is the collaboration to build a new wind farm with a total installed capacity of 199.5 MW and a total of 133 wind turbines with a capacity of 1,500 kW per unit in China -which convert wind resources into clean electricity that is exported to the electricity grid in northern China-, which has allowed the company to offset 665 tons of CO<sub>2</sub>.

### **About ESTEVE**

ESTEVE ([www.esteve.com](http://www.esteve.com)) is an international pharmaceutical company with headquarters in Barcelona. Its mission is to advance in innovation to improve the lives of people and, since it was founded in 1929, it has focussed on providing solutions for medical needs that are not yet covered. ESTEVE has a significant presence in Europe and the USA. The company operates in the US through subsidiaries and its own production facilities dedicated to the development and manufacture of active pharmaceutical ingredients in Spain, Mexico and China, as well as a pharmaceutical plant in Germany.

### **For further information, please contact:**

Olga Cajal, ESTEVE Communications, Tel. 93 446 62 60, [ocajal@esteve.com](mailto:ocajal@esteve.com)  
M<sup>a</sup> José Egea, Atrevia, Tel. 93 419 06 30, [mjegea@atrevia.com](mailto:mjegea@atrevia.com)